- Home
- ICON vs KALA Comparison
ICON vs KALA Comparison
Compare ICON & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICON | KALA |
|---|---|---|
| Founded | 2023 | 2009 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.7M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ICON | KALA |
|---|---|---|
| Price | $0.93 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.1K | ★ 294.6K |
| Earning Date | 08-14-2026 | 11-23-2026 |
| Dividend Yield | ★ 5000.00% | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $57.25 | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.07 |
| 52 Week High | $4.23 | $191.00 |
Technical Indicators
Market Signals| Indicator | ICON | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 32.11 |
| Support Level | $0.84 | $0.11 |
| Resistance Level | $0.98 | $0.35 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 26.32 | 13.45 |
Price Performance
Historical ComparisonAbout ICON Icon Energy Corp.
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
About KALA KALA BIO Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.